Vi bøger
Levering: 1 - 2 hverdage

Kemisk, bioteknologisk og farmaceutisk industri

Her finder du spændende bøger om Kemisk, bioteknologisk og farmaceutisk industri. Nedenfor er et flot udvalg af over 42 bøger om emnet. Det er også her du finder emner som Petrokemisk og plastindustri. Værker, som handler om disse brancher fra et industri-/brancheperspektiv. Se også TDC* Industriel kemi og kemiteknik.
Vis mere
Filter
Filter
Sorter efterSorter Populære
  • af Lars Holger Ehlers
    292,95 kr.

    Medical Market Access refererer til barrierer der findes i et land, ved introduktion af nye lægemidler til behandling af patienter. Denne lærebog introducerer læseren til medicinsk markedsadgang med stærkt fokus på Danmark og det danske marked for lægemidler; det beskriver karakteristika for det danske marked for lægemidler og dets interessenter og processerne af markedsgodkendelse og godtgørelse. Bogen tager også et virksomhedsperspektiv og forklarer hvordan branchen arbejder med medicinske markedsadgangsproblemer på dansk daglig praksis. For at sætte det danske marked i perspektiv forklares bogen også både samfundsmæssige dilemmaer og internationale medicinske markedsforhold. Bogen er udarbejdet til kandidat-niveau, men selve forståelsen af de nationale og internationale spørgsmål om medicinsk markedsadgang er i stigende grad vigtigt for både fagfolk, der arbejder i sundhedssystemet og den medicinske industri. Denne bog er den første af sin art, der introducerer et udviklende område af betydning ikke kun for industrien som helhed, men også for udbydere, patienter, investorer og tilsynsorganer i Danmark. Lars Holger Ehlers, Ph.D., er professor på the Danish Center for Healthcare Improvements, Institut for Erhverv og Ledelse, Aalborg Universitet. Han har skrevet et stort antal artikler om sundhedsøkonomi og underviser kurser på Aalborg Universitet.

  • af Martin G Vantrieste
    211,95 - 354,95 kr.

  • af Anton Pottegård & Tore Bjerregaard Stage
    358,94 kr.

    En præcis og opslagsvenlig guide til brug af lægemidler i praksis – nu i 3. udgave."Praktisk farmakologi" henvender sig til den sundhedsprofessionelle, der har brug for et overblik over den praktiske brug af receptpligtige lægemidler og håndkøbslægemidler – særligt farmaceutstuderende og farmakonomer, men også hjemmesygeplejersker, medicinstuderende og læger.Denne 3. udgave er blevet grundigt opdateret og væsentlig forbedret med den nyeste viden og et væld af erfaringer fra klinisk praksis. Bogen indeholder kort og præcis information om de 100 mest solgte lægemiddelgrupper i Danmark. Bogen giver dig: lægemidlernes navne, hvilke sygdomme de bruges til at behandle, hvordan de virker, de vigtigste bivirkninger, særlige oplysninger.Bogen gennemgår desuden de 25 hyppigste problemer, som kan løses ved brug af håndkøbslægemidler, samt de vigtigste fakta om naturlægemidler, lægemiddelinteraktioner, receptlovgivningen og reglerne for tilskud til medicin.

  • af Mehrnaz Campbell
    239,95 kr.

    We're battling Zoom fatigue. We're burnt out. We're a lost generation, clawing our way through endless economic permacrisis. The pharma industry, in response, has lunged towards digital transformations and omnichannel implementations, yet very little has improved as a result. In fact, it feels as though things have only gotten worse. The COVID pandemic has a lot to answer for, and the problems pharma faced as a result of the pandemic have only been compounded by this digital transformation. Many executives and field teams have found themselves lost amidst constant reorganisations, unsure how get back to the performance levels they had before. Enter The Omni Advantage by Mehrnaz Campbell, a beacon of clarity in this digital fog. Herein lies a vision for a future that is secure and effective. It urges leaders to rediscover the timeless currency of trust and authentic communication in a digital age. Campbell expertly guides professionals on how they can focus on what truly matters. Specifically, she shows them how to bypass the distractions of the shiny objects and how to home in on the meaningful human connections that have always formed the industry's cornerstone. With insightful examples and actionable advice, you have in your hands an essential ally for the commercial, medical, and marketing leaders who want to see beyond these turbulent times. It's a concise roadmap to rebuilding confidence, enhancing quality, and fostering genuine engagement in an industry poised for meaningful change. Seize the advantage-the Omni Advantage!

  • af Francisco de Latorre Quiñónez
    110,95 - 122,95 kr.

  • af Kalyani Prusty
    240,95 kr.

    Carbohydrates indicate to a group of organic compounds which includes C, O, and Hgenerally in the form of 1: 2: 1 ratio and mainly comprises of cellulose, sugars, starch etc.Formerly, the carbohydrates are observed as hydrates of carbon and resemble to general formula(C.H2O) n. But the name of the group 'carbohydrates' occasionally found misleading because: (i)some organic compounds e.g., acetic acid (CH3COOH), formaldehyde (HCHO), inositol(C6H12O6), lactic acid (C3H6O1), etc. corresponds to the general formula but is not carbohydrates.(ii) It is found that the above general formula does not correspond to some carbohydrates e.g.,digitoxose (C6H12O4), rhamnose (C6H12O5), rhamnohexose (C7H14O6) (iii) besides comprising ofC, O and H, some carbohydrates also carry sulphur and nitrogen. Thus, the carbohydrates aremore suitably referred to as polyhydroxyaldehydes and their derivatives or the substances whichyield these on hydrolysis.

  • af D K Tripathi
    539,95 kr.

    In the profession of pharmacy, Industrial Pharmacy is an important area because it is a discipline that involves manufacturing, analysis (quality control), quality assurance, formulation development, marketing, and distribution of various drug products. Accordingly, the students are supposed to understand the manufacturing and evaluation of different types of drug products. They should know why and how the preformulation studies are carried out. This has been expected that after completion of the subject the students are expected to know the various pharmaceutical dosage forms and their methods of manufacturing, various aspects of the development of pharmaceutical dosage forms, preparation, and evaluation of different types of solid, liquid, and semisolid dosage forms. The book has been prepared with great care utilizing simple language so that the reader from any background can understand the concept easily. The book has 10 chapters comprising the syllabus has been divided into 10 chapters-Preformulation studies, Tablet, Capsules, Pellets, Liquid orals, Aerosol products, Cosmetics, Parenteral Products, Ophthalmic products, Packaging Material Sciences. Although the author has taken various steps to make the book error free, despite this if any mistake in spelling or in meaning is found, please do not hesitate to inform the author so that necessary corrective measures can be taken.

  • af Steve Clarke
    269,95 kr.

    Based on his years of frontline experience, Steve Clarke shows you how to uncover and address the critical gaps in your Life Science supply chain and build long-term capability.

  • af Bayya Subba Rao
    894,95 kr.

    "Intellectual Property Rights in Pharmaceutical Industry: Theory and Practice" is an exclusive book shedding light on the fundamental concepts of intellectual property protection, with a special emphasis on pharmaceuticals. The book explores how the importance of intellectual property rights has grown in the last few decades, especially in India, after signing the World Trade Organisation agreement. The book explains how the Indian government has made necessary amendments in the intellectual property laws, built infrastructure, and even introduced topics related to intellectual property rights in the academic curriculum.The book dives deeply into the Indian patent system, with case studies from US and Indian courts serving as examples, to provide a better understanding of the system. The third edition is a result of the major administrative changes observed in the Indian government in recent years.This book is aimed at students, industry professionals, scientists, regulators, and policymakers interested in the pharmaceutical industry. This book serves as a valuable resource for B. Pharm, Pharm D, M. Pharm, and Ph.D. level students, along with other science educational programs in all the Universities of India. On reading this book, the pharmaceutical community will gain a better understanding of the intellectual property protection system, leading to an orientation of research development to ensure intellectual property protection.This book is a must-have for anyone involved in the pharmaceutical industry who wants to understand the nuances of intellectual property protection in India.

  • af Steve Clarke
    153,95 kr.

    In today's dynamic and high-stakes business landscape, companies are in continual pursuit of strategies to boost productivity, curtail wasteful efforts, and achieve greater effectiveness, efficiency, and profitability. Teams are constantly under scrutiny of performance metrics and systems meant to underpin objectives to support company goals. Anticipated challenges stemming from exponential growth and unforeseen disruptions such as a global pandemic put strain on even the most robust and seemingly well working systems, exposing flawed systems and growth opportunities for all, supply chains included.What should you do when your organization is on the verge of outgrowing its processes and capabilities? What can you do when band-aids holding supply chain systems in place are losing their stronghold? And, more importantly, how can you proactively prevent or mitigate supply chain issues?In Mine the Gaps, Steve Clarke, an experienced professional in the field of life science supply chain operations, shares invaluable insights into his tried-and-true methodology to prevent common supply chain issues with effective process design and execution. Drawing from years of hands-on experience, Clarke understands that when things feel chaotic and out of control, it's essential to focus on what is within your span of control. And one of the most powerful tools at your disposal is a well-defined framework for identifying gaps and bridging them, transforming your business operations, supply chain processes, and business outcomes along the way.Too often businesses waste time on scorecards, dashboards, and analytics that provide them with little or no insight. Clarke reveals how to leverage readily available data that will result in quick wins and select relevant metrics that are actionable and drive better business decisions.In Mine the Gaps, readers can expect to:¿ Learn 7 process redesign principles that will transform how work gets done.¿ Uncover pitfalls to avoid and how to put measures in place for prevention efforts.¿ Explore a tested and realistic roadmap for companies to leverage and tailored to their specific needs.Clarke underscores the notion that process improvement and operational innovation are key drivers of superior outcomes. Through actionable insights, real-world examples, and proven strategies to help overcome challenges and achieve supply chain excellence, Mine the Gaps offers a powerful and comprehensive framework that empowers businesses to achieve supply chain excellence and organizational success. Unlock the full potential of your supply chain, optimize operations, and position yourself at the forefront of your industry.

  • af Evan Hughes
    142,95 kr.

    "The blistering inside story of a startup that made millions pushing opioids-until its cutthroat tactics were exposed and its executives put behind bars John Kapoor had amassed a small fortune in pharmaceuticals when he conceived of a new product. It was the 2000s, and opioids were big business. If Kapoor, an immigrant and the billionaire founder of Insys, could find a new way to administer the highly potent fentanyl, he could patent his invention and sell it to those in need-at a steep price. The only problem: There weren't enough people in need. Kapoor's drug was approved for breakthrough cancer pain. If Subsys was going to turn a profit, the company would need to persuade doctors to prescribe it "off-label," for other, lesser forms of pain. This is the story of how Insys turned a niche drug into big business. With executives leading the charge, Insys sales reps seduced doctors with charm, money, and sex. Its administrators lied to health care providers, claiming recipients had cancer when they did not. It pushed drugs onto patients that would have benefited from safer options, or no drugs at all. The strategy worked: When Insys went public, it notched the biggest IPO of its year. But several employees reached their limit and quietly blew the whistle, bringing the full force of the justice system upon the drug maker. In The Hard Sell, author and National Magazine Award-finalist Evan Hughes lays bare the pharma playbook. He shows how drug makers like Insys, fueled by greed and a hunger for market share, turn deception into profit. The book represents a stunning vindication, but also a cautionary tale. As Hughes shows, Insys didn't do anything its competitors weren't also doing. It was simply worse at covering its tracks"--

  • af Peter M. Caballero
    317,95 kr.

    Our world is threatened by serious global climate changes and socioeconomic concerns.Most climate scientists agree that the major cause of the current global warming is the heatentrapped by the atmosphere, which is radiating from the earth into space; a phenomenon calledthe greenhouse effect (D. Lee & Brenner, 2015). Researchers have warned that carbon dioxideand other greenhouse gas emissions (water vapor, methane, and nitrous oxide) are at their highestlevel worldwide ever (Burney, Kennel, & Victor, 2013). The burning of fossil fuels such as coaland oil throughout the past century has increased the atmospheric concentration of carbondioxide. The amount of these gases released into the atmosphere in 2010 was 31% higher thanthe 1990. The increase in global temperatures as a result of climate change has far-reachingconsequences for human beings and the earth's ecosystems

  • af Wai Yie Leong
    1.642,95 kr.

    This book covers computer-integrated equipment manufacturing, which allows high levels of adaptability and rapid equipment design changes to enable smart manufacturing processes. Benefits of the integration of lean manufacturing, smart sensors, 5G technology, IoTs, virtual reality, 3D printing, robotics and automation, are discussed.

  • af Murat Kulahci
    467,95 kr.

  • af Paul Kusserow
    284,95 kr.

    An extraordinary case study of a home healthcare business turnaround delivers actionable strategies for driving profit and growth in your organizationWhen Paul Kusserow began working as a consultant for Amedisys, the company was on the brink of collapse. Its stock had fallen to under $11 per share, and it had to borrow money to pay a massive government fine. Six months later, Kusserow became its CEO. Under his leadership, the company dramatically improved operations, increased its stock value to as high as $325 per share, and took its place among the top home care and hospice businesses in the country.In this inspiring in-depth case study, Kusserow explains how he achieved the seemingly impossible, providing invaluable lessons you can use to breathe new life into your organization. Unlocking unrealized human potential has the highest return of any and all strategic investments. The keys, Kusserow explains, are a recommitment to the core mission of caring and the implementation of a Golden Rule managerial model that emphasizes treating employees well and listening to their performance improvement advice. These twin governing principles were essential to delivering great outcomes, retaining and attracting staff, as well as turbocharging organizational performance and profitability. Amedisys reimagined and redefined the home care industry, and its people had powered its transformation.Kusserow reveals concrete leadership and life lessons that were responsible for the four phases of Amedisys's evolution-turnaround, stability, growth, and transformation-into the nation's leading and most innovative home care company. It's a proven framework for any business turnaround.

  • af Nick Dearden
    185,95 kr.

    How Big Pharma failed to end a pandemic, and what it tells us about the global economy

  • af Subba Rao Chaganti
    697,95 kr.

  • af Scott Howard
    387,95 - 572,95 kr.

  • af Subba Rao Chaganti
    397,95 kr.

  • af Evan Hughes
    105,95 - 145,95 kr.

  • af Brandon J. Weichert
    215,95 kr.

    When COVID-19 erupted from Wuhan, China under mysterious circumstances, the Communist Party of China covered up its existence for as long as possible. It is now apparent that there is more to COVID than what the authorities wish for us to know. Biohacked: China’s Race to Control Life details the decades-long pursuit by the Chinese Communists to dominate the biotechnology industry—to control the very building blocks of life on Earth—to further their political control at home and their supremacy abroad. More appalling than the egregious cover-up that China’s rulers engaged in with COVID-19 is the fact that Western scientists, pharmaceutical companies, and research labs have contributed to China’s rapid (and dangerous) growth in the biotech industry—so much so that China, not the United States, may become the seat of the biotechnology industry. The Chinese leadership believes that biotechnology is a critical industry for the Communist Party to achieve its goal of becoming the world’s dominant superpower by 2049. In China’s biotech sector, truly macabre practices are being developed, from ambitious cloning programs to the creation of potential pathogens that China’s military plans to use in “specific genetic attacks” against Beijing’s growing list of political enemies.To stop the threat, author Brandon J. Weichert proposes the world’s nations create a comprehensive set of treaties for regulating biotechnology research and development. Further, Weichert calls for Washington to slow the transfer of advanced biotechnology knowledge and funding from the United States to China using means like the Foreign Corrupt Practices Act and the Committee on Foreign Investment in the United States (CFIUS). Unless an all-of-government (and society) approach is taken to curbing irresponsible biotech development in China, then another—deadlier—COVID-19-like pandemic could be at hand.

  • af Robert G. Mortimer
    592,95 kr.

    Mathematics for Physical Chemistry, Fifth Edition includes exercises that enable readers to test their understanding and put theory into practice. Chapters are constructed around a sequence of mathematical topics, progressing gradually into more advanced material, before discussing key mathematical skills, including the analysis of experimental data and¿new to this edition¿complex variables. Includes additional new content on Mathematica and its advanced applications. Drawing on the experience of its expert authors, this book is the ideal supplementary text for practicing chemists and students wanting to sharpen their mathematics skills and understanding of key mathematical concepts for applications across physical chemistry.

  • af Charles Theuer
    317,95 kr.

    The drug development process in the United States has become so weighted down by a business-as-usual paradigm that an average of more than $2 billion is spent to secure FDA approval for every new drug. Because the investment required is so extreme, drug development companies are understandably focused on discovering and developing drugs designed for large patient populations: diseases experienced by millions, such as high blood pressure, diabetes, or some of the more common cancers. In Unnecessary Expense, Dr. Charles Theuer, CEO of TRACON Pharmaceuticals, outlines the problem and offers a solution: an aligned and streamlined model that emphasizes quality and reduces the time and cost of drug development, while also harnessing global innovation to benefit patients with rare diseases in urgent need of new treatments. Here Dr. Theuer shows the value of a pharmaceutical paradigm shift, to enable the development of drugs for patients who need them, at a fraction of the time and cost.

Gør som tusindvis af andre bogelskere

Tilmeld dig nyhedsbrevet og få gode tilbud og inspiration til din næste læsning.